KrillYoplait
This article was originally published in The Tan Sheet
Executive Summary
Neptune Technologies & Bioressources announces June 19 a partnership with Yoplait to develop new functional dairy products for worldwide commercialization. Yoplait will launch dairy products containing Neptune Krill Oil in "strategically chosen countries followed by a worldwide rollout," Neptune says. The firm will supply Yoplait with NKO and will receive an upfront fee as well as milestone payments and distribution royalties, Neptune states. This is not Yoplait's first venture into functional yogurt; in January Yoplait announced it added Martek's life'sDHA to its kids line (1"The Tan Sheet" Jan. 22, 2007, In Brief)...
You may also be interested in...
Neptune shifts operations
Neptune Technologies & Bioresources transfers the license for its cardiovascular application portfolio to operating subsidiary Acasti Pharma to develop active pharmaceutical ingredients for products in the Rx, OTC and medical food markets, the firm announces Aug. 21. Under the arrangement, Quebec-based Acasti will research, develop and market the APIs, with the goal of entering strategic pharmaceutical partnerships. Neptune announced a deal with Yoplait in June 2007 to provide its Neptune Krill Oil - a composition with proprietary omega-3 phospholipids - for use in functional yogurt products (1"The Tan Sheet" July 2, 2007, In Brief)
Functional yogurt
Martek Biosciences announces Jan. 11 General Mills has added Martek's life'sDHA to the Yoplait Kids line. "This 'on-the-go' yogurt product will provide health-conscious parents with a unique, high quality, nutritious selection to give their children," the company says. The 4 oz. product with "25% less sugar" will available at retailers nationwide in mid February, according to the firm. In related news, Dannon announces Jan. 8 it will add Lactobacillus GG to its Danimals line of drinks specifically made for children in April...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”